SCHEMBL6505486

SCHEMBL6505486

CC(C)(C)OC(=O)N1C[C@@H](CO)[C@H](O)C1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.59
PDE4B Q07343 2/20 0.45
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
NAMPT P43490 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
HPGD P15428 1/20 0.40
RECQL P46063 1/20 0.38
EPHX1 P07099 1/20 0.38
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
RORC P51449 1/20 0.36
EPHX2 P34913 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10305448 1.00 NR1H2 (0.59) NR1H2PDE4BUSP2SMN1; SMN2CHRM2
SCHEMBL500787 1.00 NR1H2 (0.59) NR1H2PDE4BUSP2SMN1; SMN2CHRM2
SCHEMBL500788 1.00 NR1H2 (0.59) NR1H2PDE4BUSP2SMN1; SMN2CHRM2
SCHEMBL4736582 1.00 NR1H2 (0.59) NR1H2PDE4BUSP2SMN1; SMN2CHRM2
SCHEMBL30721755 0.91 NR1H2 (0.65) NR1H2PDE4BUSP2SMN1; SMN2CHRM2
SCHEMBL1014216 0.91 NR1H2 (0.65) NR1H2PDE4BUSP2SMN1; SMN2CHRM2
SCHEMBL2930155 0.91 NR1H2 (0.65) NR1H2PDE4BUSP2SMN1; SMN2CHRM2
SCHEMBL2937360 0.91 NR1H2 (0.65) NR1H2PDE4BUSP2SMN1; SMN2CHRM2
SCHEMBL9972997 0.88 NR1H2 (0.53) NR1H2PDE4BUSP2SMN1; SMN2CHRM2
SCHEMBL19083300 0.88 NR1H2 (0.53) NR1H2PDE4BUSP2SMN1; SMN2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025137053-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2025-06-26 WO disclosed
US-20250197374-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2025-06-19 US disclosed
EP-4547658-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF Bristol-Myers Squibb Company (US) 2025-05-07 EP disclosed
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-04-24 US disclosed
WO-2025064718-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-27 WO disclosed
US-12065430-B2 Indazole compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-08-20 US disclosed
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES CILAG AG (CH) 2024-05-30 US disclosed
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2024-02-29 US disclosed
WO-2024006881-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-04 WO disclosed
EP-4284802-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES Janssen Biotech, Inc. (US) 2023-12-06 EP disclosed
US-20230181536-A1 ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C TAIHO PHARMACEUTICAL CO LTD (JP) 2023-06-15 US disclosed
WO-2022165530-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES JANSSEN BIOTECH, INC. (US) 2022-08-04 WO disclosed
WO-2005033076-A1 METHOD FOR PREPARING 3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDINE COMPOUNDS INDUSTRIAL RESEARCH LIMITED (NZ) 2005-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12065430-B2 Indazole compound or salt thereof RCOR3, H1-3, BICRA NR1H2 1338/4885PDE4B 3125/4885USP2 3856/4885
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, NRAS NR1H2 2741/4885PDE4B 4082/4885USP2 1781/4885
US-20230181536-A1 ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C KRAS, NRAS, HRAS NR1H2 2517/4885PDE4B 3995/4885USP2 1965/4885
US-20240174662-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES SIK2, SIK1, SGK2 NR1H2 1934/4885PDE4B 2506/4885USP2 2482/4885
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof WEE1, WEE2, PPME1 NR1H2 3366/4885PDE4B 3170/4885USP2 242/4885
US-20250197374-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF WEE1, WEE2, PPME1 NR1H2 3366/4885PDE4B 3170/4885USP2 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.